RxDoctor Payments DataLook up a doctor →

Katia Hall

Psychiatric/Mental Health · Chesapeake, VANPI 1366865842

Payments from drug & device makers

$87,812in general payments, 2019–2025

Across 846 payments — averaging $103.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$66K
  • Neuronetics, Inc.$8K
  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $8K from 31 others

What the payments were for

  • Consulting fees$13,45515%
  • Speaking & faculty fees$42,71049%
  • Travel & lodging$11,04013%
  • Food & beverage$20,50723%
  • Education$990%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,812 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$71,902
Medicare patients
61
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl82$116,738
VraylarCariprazine Hcl24$35,223
Aripiprazole94$29,389
TrintellixVortioxetine Hydrobromide19$14,790
Ziprasidone Hcl13$2,746
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine85$2,489
Clozapine24$2,477
Divalproex Sodium41$1,613
Quetiapine Fumarate104$1,376
Fluoxetine Hcl53$1,339
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine25$1,309
Thioridazine Hcl13$1,303
Oxcarbazepine41$1,064
Bupropion XlBupropion Hcl53$887
Trazodone Hcl91$794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$65,699$116,73882 claims
AbbVieVraylar$2,732$35,22324 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$655$14,79019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →